Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin and ranolazine for prevention of trastuzumab-induced cardiac dysfunction in HER2-positive breast cancer
TCTR20231110007Phase 3Recruiting
- Sponsor
- National Science and Technology Development Agency
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin, ranolazine in breast cancer, heart failure (HF), sponsored by National Science and Technology Development Agency. Started Sep 2020; status: recruiting.
02
Drugs
melatoninranolazine
03
Conditions
breast cancerheart failure (HF)
Beyond the preview
Go deeper on TCTR20231110007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20231110007.